RichardJO'ReillyMD

Pediatric Hematology & Oncology • New York, NY

Attending, Department of Pediatrics

Overview of Dr. O'Reilly

Dr. Richard O'Reilly is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and NYC Health + Hospitals / Bellevue. He received his medical degree from University of Rochester School of Medicine and Dentistry and has been in practice 49 years. Dr. O'Reilly accepts several types of health insurance, listed below. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 14 doctors at NYC Health + Hospitals / Bellevue who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(925) 402-1692

Education & Training

Brigham and Women's HospitalResidency, Internal Medicine, 1971 - 1973
M Health FairviewInternship, Transitional Year, 1968 - 1969
University of Rochester School of Medicine and DentistryClass of 1968

Certifications & Licensure

NY State Medical License 1973 - 2025
American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Start of enrollment: 1995 Mar 01
Completed
Phase 1, Phase 2
T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia Start of enrollment: 1995 Nov 01
Completed
Phase 2
Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) Start of enrollment: 2007 Oct 16
Completed
Phase 1
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation Start of enrollment: 2008 Feb 08
Completed
Phase 1
Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants Start of enrollment: 2007 Aug 01
Completed
Phase 1
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies Start of enrollment: 2010 May 03
Completed
Phase 2
Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
Enrolling by invitation
Patients Treated for SCID (1968-Present) Start of enrollment: 2011 May 15
Enrolling by invitation
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Start of enrollment: 2011 Dec 01
Completed
Phase 2
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor Start of enrollment: 2012 May 02
Terminated
Not Applicable
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2012 Jul 13
Completed
Phase 2
Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2014 May 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

58 citations
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.
Shakeel Modak, Jean-Benoît Le Luduec, Irene Y. Cheung, Debra A. Goldman, Irina Ostrovnaya
Oncoimmunology. 2018-05-10
124 citations
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.
Richard E. Champlin, Jakob Passweg, Mei-Jie Zhang, Philip A. Rowlings, Corey J. Pelz
Blood. 2000-06-15
157 citations
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J Curran, Steven P. Margossian, Nancy A. Kernan, Lewis B. Silverman, David A. Williams
Blood. 2019-12-26

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Richard O'Reilly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on C...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual MeetingDecember 3rd, 2018
Don't Miss Out!November 1st, 2018
Shop TalkAugust 10th, 2016
Join now to see all

Grant Support

A Retrospective And Cross- Sectional Study Of Hematopoietic Cell TransplantationNational Institute Of Allergy And Infectious Diseases2011
EBV Specific T-Cells From 3rd Party Donors For Treatment Of Ebv-Associated MalignNational Cancer Institute2011
Development &Evaluation Of Practicable Approaches For Generation Of Cytotoxic &National Cancer Institute2007–2011
Clinical Trials Of Allogeneic Stem Cell Transplant In Lymphohematopoietic DisordeNational Cancer Institute2007–2011
The Immunobiology Of Marrow Allografts For LeukemiaNational Cancer Institute2002–2011
Artif. Antigen Presentation To Sensitize Virus-Spec. Tcells For Adoptive ImmunothNational Cancer Institute2006–2010
Project 5National Cancer Institute2005–2009
Molecular Targeting Of Developmental Cancers In ChildrenNational Cancer Institute2005–2009
Core DNational Cancer Institute2005–2009
Cellular Immunity Targeting Epithelial Ovarian CancerNational Cancer Institute2005–2009
IL-7 For Immune Recovery After Hematopoietic AllograftsNational Heart, Lung, And Blood Institute2001–2008
Administrative CoreNational Cancer Institute2007
T Cell Recognition Of Host Leukemia &Control Of CellsNational Cancer Institute2002
Core--Biostatistics CoreNational Cancer Institute2002
Clinical Trials Of Allogenic BMT / Stem Cell TransplantsNational Cancer Institute2002
T Lymphocytes For Treatment Of Ebv-Related LymphomaNational Cancer Institute2000–2002
Suicide Gene Modified EBV Antigen Sensitized T Cells For EBV Related LymphomaNational Cancer Institute1997–2001
Clinical Trials In Marrow TransplantationNational Cancer Institute1997–2001
Biology And Genetics Of Marrow Allografts For LeukemiaNational Cancer Institute1993–2001
Genetically Modified T Lymphocytes For Treatment Of Ebv-Related LymphomaNational Cancer Institute1997–1999
EBV B Cell Lymphomas And SCIDNational Heart, Lung, And Blood Institute1997
Experimental Approaches To Clinical TransplantationNational Cancer Institute1996
A Murine Model For Examining The Antileukemic Effect Of A Marrow AllograftNational Cancer Institute1996
EBV B Cell Lymphomas And SCID MiceNational Heart, Lung, And Blood Institute1994–1996
Cytokines In Genetic And Acquired Hemopoietic DisordersNational Institute Of Allergy And Infectious Diseases1991–1993
Marrow Transplantation In Leukemia And Other DiseasesNational Cancer Institute1988–1992
Marrow Transplant/Scid/Lethal Congenital ImmunodefiencyNational Cancer Institute1989–1990
Marrow Transp./Scid &Other Lethal Congenital Immunodef.National Cancer Institute1987–1988
Marrow Transplantation In Leukemia &Blood DiseasesNational Cancer Institute1985–1988
Transplantation Of Lethal Congenital ImmunodeficienciesNational Cancer Institute1985

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment